Eisai R&d Management Co., Ltd.

Paschalis Dimopoulos

Afzal Khan

Yoichi Kita

Toshihiko Kaneko

Yuichi Suzuki

Mamoru Takaishi

Noboru Yamamoto

Takafumi Motoki

Kunitoshi Takeda

Tasuku Ishida

Christopher Neil Farthing

Piotr Pawel Graczyk

Gurpreet Singh Bhatia

Adrian Hall

Andrew Madin

Nicola Louise Shuker

A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a Caryl group or the like, L is &#x2014;NRCO&#x2014; or the like (wherein Ris a hydrogen atom or the like), Ring B is a Caryl group or the like, X is a Calkylene group or the like, Y is a single bond or the like, Z is a Calkylene group or the like, Rand Rare each independently a hydrogen atom or the like, and R, R, Rand Rare independently a hydrogen atom, a halogen atom or the like, has an A&#x3b2; production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A&#x3b2; and typified by Alzheimer-type dementia.

Fused aminodihydrothiazine derivatives

The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein

The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.

7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase

The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.

Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase

Growing community of inventors

London, United Kingdom

Paschalis Dimopoulos